Use Of Medulliadrenal Chromaffin Cells Or Peptide Functional Cells

A medicine of microencapsulated bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering for treating or relieving withdraw syndrome, characterized in that said medicine is prepared by the following steps:

• (1) mixing the bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering with a sodium alginate solution of 10-20 g/L to form a suspension, said suspension containing 0.1-1010 cells per liter;
• (2) dispersing the suspension of step (1) into a calcium chloride or calcium lactate solution of 80-120 mmol/L in the form of droplets of 150-1000 μm in diameter using a spraying device, the two liquids being in such a proportion that the resulting mixture contains 0.1-1×108 cells per liter, leaving to stand for 5-20 minutes, discarding the supernatant after complete precipitation, to obtain the calcium alginate bead precipitates comprising bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering;
• (3) adding the precipitates from step (2) into a polylysine solution of 0.3-0.7 g/L in such a proportion that the resulting mixture contains 0.2-2×108 cells per liter, mixing thoroughly, leaving to stand for 5-20 minutes, discarding the supernatant after complete precipitation, to obtain the precipitates;
• (4) adding the precipitates from step (3) into a sodium alginate solution of 1.0-2.0 g/L in such a proportion that the resulting mixture contains 0.2-2×108 cells per liter, mixing thoroughly, leaving to stand for 3-15 minutes, discarding the supernatant after complete precipitation, to obtain the precipitates;
• (5) adding the precipitates from step (4) into a sodium citrate solution of 40-70 mmol/L in such a proportion that the resulting mixture contains 0.2-2×108 cells per liter, mixing thoroughly, leaving to stand for 5-20 minutes, discarding the supernatant after complete precipitation, to obtain the precipitates of microencapsulated bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering;
• (6) washing the precipitates from step (5) by adding them into a sodium chloride solution of 9 g/L, finally transferring the precipitates into a cell culture, culturing and storing as a medicine of microencapsulated bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering for treating or relieving withdrawl syndrome.